CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 50 enrolled
Drug / intervention
Prolensa (bromfenac 0.07%) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01847638
NCT01847638N/ACompleted
CompareCT.gov

Clinical Outcomes of Prolensa (Bromfenac Ophthalmic Solution) 0.07% QD vs. Ilevro (Nepafenac Ophthalmic Suspension) 0.3% QD for Treatment of Ocular Inflammation Associated With Cataract Surgery

Melissa Toyos·interventional·Posted May 7, 2013·Updated Nov 14, 2018

In Brief

A clinical study evaluating Prolensa (bromfenac 0.07%) and Ilevro (nepafenac 0.3%) for Cataract and 2 related conditions. Completed, enrolled 50 participants across 1 site.

Detailed Summary

To investigate inflammation, visual acuity and macular thickness after treatment with Prolensa vs Ilevro after cataract surgery.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCataract, Retinal Edema, Inflammation
CountriesUnited States
CollaboratorsBausch & Lomb Incorporated

Timeline

N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedMay 7, 2013
Enrollment StartApr 1, 2013
Primary CompletionJul 16, 2016
Study CompletionAug 23, 2018
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 13.2 years ago

Interventions

Prolensa (bromfenac 0.07%)drug

Comparison of Prolensa (bromfenac ophthalmic solution) 0.07% QD vs. Ilevro (nepafenac ophthalmic suspension) 0.3% QD for Treatment of Ocular Inflammation Associated with Cataract Surgery

Ilevro (nepafenac 0.3%)drug

Comparison of Prolensa (bromfenac ophthalmic solution) 0.07% QD vs. Ilevro (nepafenac ophthalmic suspension) 0.3% QD for Treatment of Ocular Inflammation Associated with Cataract Surgery